Abstract
Atherosclerosis is driven by inflammation with an involvement of innate and adaptive immune responses. Toll-like receptors, the well-defined pattern recognition receptors of the immune system, play a central role in macrophage activation. Toll-like receptors recognize pathogen-associated molecular patterns expressed by a wide range of infectious agents and provide a strong link between local innate and adaptive immunity. Activation of these receptors triggers an intracellular signaling cascade mediated through myeloid differentiation factor 88 or toll/interleukin-1 receptor-domain-containing adapter-inducing interferon-β, leading to the secretion of proand anti-inflammatory cytokines. Engagement of Toll-like receptors with their ligands induces leukocyte recruitment and enhances matrix metalloproteinase expression within atherosclerotic lesions. Recently certain Toll-like receptors have shown a protective role in atherosclerosis. TLRs, therefore, represent an important link between inflammation and atheroma, making them attractive targets for the treatment of atherosclerosis. This review will briefly describe the general biological structure and potential roles of Toll-like receptors as therapeutic targets for the treatment of atherosclerosis and highlight the potential challenges on Toll-like receptor- based therapy in cardiovascular disease.
Keywords: Toll-like receptor, atherosclerosis, inflammation, plaque, cardiovascular disease, knock out mouse.
Current Medicinal Chemistry
Title:Essential Roles of Toll-Like Receptors in Atherosclerosis
Volume: 23 Issue: 5
Author(s): Juntang Lin, Vijay Kakkar and Xinjie Lu
Affiliation:
Keywords: Toll-like receptor, atherosclerosis, inflammation, plaque, cardiovascular disease, knock out mouse.
Abstract: Atherosclerosis is driven by inflammation with an involvement of innate and adaptive immune responses. Toll-like receptors, the well-defined pattern recognition receptors of the immune system, play a central role in macrophage activation. Toll-like receptors recognize pathogen-associated molecular patterns expressed by a wide range of infectious agents and provide a strong link between local innate and adaptive immunity. Activation of these receptors triggers an intracellular signaling cascade mediated through myeloid differentiation factor 88 or toll/interleukin-1 receptor-domain-containing adapter-inducing interferon-β, leading to the secretion of proand anti-inflammatory cytokines. Engagement of Toll-like receptors with their ligands induces leukocyte recruitment and enhances matrix metalloproteinase expression within atherosclerotic lesions. Recently certain Toll-like receptors have shown a protective role in atherosclerosis. TLRs, therefore, represent an important link between inflammation and atheroma, making them attractive targets for the treatment of atherosclerosis. This review will briefly describe the general biological structure and potential roles of Toll-like receptors as therapeutic targets for the treatment of atherosclerosis and highlight the potential challenges on Toll-like receptor- based therapy in cardiovascular disease.
Export Options
About this article
Cite this article as:
Lin Juntang, Kakkar Vijay and Lu Xinjie, Essential Roles of Toll-Like Receptors in Atherosclerosis, Current Medicinal Chemistry 2016; 23 (5) . https://dx.doi.org/10.2174/0929867323666151207111408
DOI https://dx.doi.org/10.2174/0929867323666151207111408 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity
Current Pharmaceutical Design Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Treatment of Foot Disease in Patients with Type 2 Diabetes Mellitus using Human Umbilical Cord Blood Mesenchymal Stem Cells: Response and Correction of Immunological Anomalies
Current Pharmaceutical Design Possible Underestimation by Sports Medicine of the Effects of Early Physical Exercise Practice on the Prevention of Diseases in Adulthood
Current Diabetes Reviews Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets
Current Pharmaceutical Design Endocannabinoid Receptor Antagonists and Other Emerging Pharmacological Strategies for Weight Reduction
Current Drug Targets - Cardiovascular & Hematological Disorders Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Quantification of Shear Stress and Geometric Risk Factors in Carotid Atherosclerosis: Review and Clinical Evidence
Recent Patents on Medical Imaging Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology The Assessment of Interleukin-18 on the Risk of Coronary Heart Disease
Medicinal Chemistry Myeloperoxidase: The Good, the Bad, and the Ugly
Current Immunology Reviews (Discontinued) Sudden Unexplained Death in Infancy and Long QT Syndrome
Current Pediatric Reviews Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy The Significance of Endothelium-Derived Hyperpolarizing Factor in the Human Circulation
Current Vascular Pharmacology Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Current Medicinal Chemistry